Drug Details
| General Information of the Drug (ID: DR3804) | ||||
|---|---|---|---|---|
| Name |
Cefuroxime
|
|||
| Synonyms |
cefuroxime; Cephuroxime; Cefuroxim; Cefuroximo; 55268-75-2; Cefuroximum; Zinacef Danmark; Zinacef; Sharox; Cefuroximum [INN-Latin]; Cefuroximo [INN-Spanish]; UNII-O1R9FJ93ED; O1R9FJ93ED; CHEBI:3515; (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Biofuroksym; Cefuril; Kefurox; Q63409033; (6r,7r)-3-[(Carbamoyloxy)methyl]-7-{[(2z)-2-(Furan-2-Yl)-2-(Methoxyimino)acetyl]amino}-8-Oxo-5-Thia-1-Azabicyclo[4.2.0]oct-2-Ene-2-Carboxylic Acid; Cefuroxime [USAN:INN:BAN]; C16H16N4O8S; (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; EINECS 259-560-1; BRN 5783190; Cefuroximine; Cefuroxime [USAN:BAN:INN]; 4kov; Cefuroxime (TN); Cefuroxime (USAN/INN); Prestwick3_000720; CHEMBL1436; BSPBio_000939; (6R,7R)-7-(2-(2-Furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid 7(sup 2)-(Z)-(O-methyloxime) carbamate (ester); 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-furanyl(methoxyimino)acetyl)amino)-8-oxo-, (6R-(6alpha,7beta(Z)))-; BIDD:GT0619; BPBio1_001033; SCHEMBL1821942; HY-B1256A; ZINC3830485; BDBM50422689; MFCD00864889; AKOS015962849; AC-4539; DB01112; KS-5162; P802; AB0010602; CS-0013520; EN300-53016; C06894; Cefuroxime, VETRANAL(TM), analytical standard; D00262; 268C752; A830563; Cefuroxime, Antibiotic for Culture Media Use Only; W-105575; BRD-K02733959-236-02-8; BRD-K02733959-236-07-7; (6R,7R)-3-((Carbamoyloxy)methyl)-7-((Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(aminocarbonyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyimino-ethanoyl]amino]-8-oxidanylidene-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(2-furanyl)-2-methoxyimino-1-oxoethyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(2-furyl)-2-methoxyimino-acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-3-[[(Aminocarbonyl)oxy]methyl]-7-[[(2Z)-2-(2-furanyl)-2-(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic Acid; 3-[(carbamoyloxy)methyl]-7beta-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-3,4-didehydrocepham-4-carboxylic acid; KEF; KOV
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Acute bronchitis [ICD-11: CA42] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| ADMET Property |
Absorption
The drug absorbed from the gastrointestinal tract
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability
Clearance
The drug present in the plasma can be removed from the body at the rate of 2.2 mL/min/kg
Elimination
96% of drug is excreted from urine in the unchanged form
Half-life
The concentration or amount of drug in body reduced by one-half in 80 minutes
Metabolism
The drug is metabolized to acetaldehyde and acetic acid
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 39.35042 micromolar/kg/day
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.15 L/kg
Water Solubility
The ability of drug to dissolve in water is measured as 200 mg/mL
Click to Show/Hide
|
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C16H16N4O8S
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CON=C(C1=CC=CO1)C(=O)NC2C3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O
|
|||
| InChI |
1S/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9-/t10-,14-/m1/s1
|
|||
| InChIKey |
JFPVXVDWJQMJEE-IZRZKJBUSA-N
|
|||
| CAS Number |
CAS 55268-75-2
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| 1,4-naphthoquinone | Setaria palmifolia | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | Micrococcus luteus | Microorganism model | Micrococcus luteus | |||
| Bacillus cereus | Microorganism model | Bacillus cereus | ||||
| Methicillin-sensitive Staphylococcus aureus | Microorganism model | Staphylococcus aureus | ||||
| Methicillin-Resistant Staphylococcus aureus | Microorganism model | Staphylococcus aureus | ||||
| Escherichia coli | Microorganism model | Escherichia coli | ||||
| Klebsiella pneumoniae | Microorganism model | Klebsiella pneumoniae | ||||
| Pseudomonas aeruginosa | Microorganism model | Pseudomonas aeruginosa | ||||
| Salmonella choleraesuis | Microorganism model | Salmonella choleraesuis | ||||
| Experimental
Result(s) |
1,4-naphthoquinone combined with ascorbate have significant antitumor effects against MCF-7 cells in vitro and Ehrlich-ascites carcinoma in mice. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Bacterial Penicillin binding protein (Bact PBP) | Molecule Info | [3] | |